Decheng Capital Global Life Sciences Fund IV, L.P.

Insider Reports History

Entity
Company
Location
C/O Maples Corporate Services Limited, Ugland House, P.O. Box 309, Grand Cayman, Cayman Islands
Signature
Decheng Capital Global Life Sciences Fund IV, L.P., By Decheng Capital Management IV (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Decheng Capital Global Life Sciences Fund IV, L.P.:

Stock Role Class Num Shares Value Price $ Report Date Ownership
CG Oncology, Inc. 10%+ Owner Common Stock 4.96M $175M $35.36 Jan 29, 2024 Direct
Aardvark Therapeutics, Inc. 10%+ Owner Common Stock 2.96M Feb 14, 2025 By Decheng Capital Global Life Sciences Fund IV, L.P.
Aardvark Therapeutics, Inc. 10%+ Owner Common Stock 958K Feb 14, 2025 By Decheng Capital Global Healthcare Fund (Master), LP
Aardvark Therapeutics, Inc. 10%+ Owner Series C Convertible Preferred Stock 0 Feb 14, 2025 By Decheng Capital Global Healthcare Fund (Master), LP
Aardvark Therapeutics, Inc. 10%+ Owner Series C Convertible Preferred Stock 0 Feb 14, 2025 By Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology, Inc. 10%+ Owner Series C Preferred Stock 0 Jan 29, 2024 Direct
CG Oncology, Inc. 10%+ Owner Series E Preferred Stock 0 Jan 29, 2024 Direct
CG Oncology, Inc. 10%+ Owner Series F Preferred Stock 0 Jan 29, 2024 Direct

Insider Reports Filed by Decheng Capital Global Life Sciences Fund IV, L.P.

Symbol Company Period Transactions Value $ Form Type Date Filed Role
AARD Aardvark Therapeutics, Inc. Feb 14, 2025 6 $20M 4 Feb 19, 2025 10%+ Owner
AARD Aardvark Therapeutics, Inc. Feb 12, 2025 0 $0 3 Feb 12, 2025 10%+ Owner
CGON CG Oncology, Inc. Jan 29, 2024 1 $7.6M 4/A Apr 9, 2024 10%+ Owner
CGON CG Oncology, Inc. Jan 29, 2024 5 $7.6M 4 Jan 31, 2024 10%+ Owner
CGON CG Oncology, Inc. Jan 24, 2024 0 $0 3 Jan 24, 2024 10%+ Owner